Astera Labs looks relatively expensive because similarly fast-growing AI infrastructure names trade at much lower multiples. Broadcom and Nvidia are at 14x, Credo at 15x and Lumentum at 18x; comparable peers look 50-80% cheaper. Astera is a great company and not necessarily expensive in absolute terms. Its roughly 2x multiple over Credo may persist, but the setup looks harder; with no valuation support, it could fall 50% if weakness continues. x.com  x.com  x.com  x.com 

Astera Labs is an incredible business, but its price leaves little margin of safety. Even an amazing decade, with revenue reaching $20B at 26% annual growth from about $1.9B, a 35% operating margin and a 30x multiple, makes it a roughly $158B company, about 3.6x from $44B, or around 13% a year before dilution. Slower revenue, lower margins, a lost customer, hyperscaler insourcing or tougher competition would erode that. Buying at half the price would make the risk/reward look amazing. x.com  … Show more

Astera Labs no longer looks expensive after falling 50% from its highs, trading below 35x NTM EBITDA with EBITDA expected to grow at a 60% CAGR for several years. Revenue is growing 105% YoY, with growth expected to accelerate for the next 2-3 quarters as margins expand. The stock is testing key support at its September 2025 highs, just above the 0.618 Fibonacci level and 200-day EMA. It is worth a look if the AI infrastructure buildout continues as planned. x.com 

Astera Labs is a great company but definitely overvalued today. Per @StockSavvyShay, it carries a PEG ratio of about 3.6x, the highest among the semiconductor stocks compared and well inside the danger zone above 2x. x.com 

Astera Labs is an extremely good, unique business but still too expensive to buy. It is founder-led, growing fast and sits at the center of the AI infrastructure buildout, selling PCIe/CXL retimers and fabric switches to AWS, Azure and Google Cloud, but its valuation keeps it on the watchlist. x.com  x.com 

Astera Labs' growth is outrunning its share price: after recent earnings, it trades at nearly half the valuation it had at the same share price before. x.com 

Astera Labs' valuation has gotten nuts given its medium- and long-term competitive and technology risks, especially next to NVIDIA and Broadcom. The aixPhotonics acquisition was smart, but even if those optical offerings ramp well, they are unlikely to offset the long-term cannibalization of retimers, AECs and similar products by NPO and CPO. x.com 

Credo is the better pick for momentum and potential returns right now, since a smaller market cap gives more torque, even though Astera Labs is fundamentally the better company. Scale-up connectivity will not be a big part of Credo's business until around FY28, so it needs to pivot into optics, while Astera is more agnostic and flexible. x.com 

Astera Labs' key fundamentals are positive and growing nicely while the stock sits 35% off its highs, consolidating back toward its 200-day moving average. Ideal buying or accumulation is near or just above that average. x.com 

Astera Labs carries a huge premium for flawless execution against a CXL market that is small near term. Switch-based CXL memory pooling capturing $15-16B in 2026-2028 is low probability: Marvell guides its XConn switch business to only about $100M by fiscal 2028, PCIe included. Pooling software likely stays immature into 2028, per a Samsung white paper, and Nvidia is contesting the warm KV-cache tier. Astera does CXL best, but SK hynix and Micron offer better risk-adjusted returns. x.com  x.com